Skip to search formSkip to main contentSkip to account menu

eribulin

Known as: halichrondrin B analog, 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one, 2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy- 26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy- 7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6) pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one 
An analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca… 
National Institutes of Health

Related topics

Related topics

13 relations
2 ML eribulin mesylate 0.5 MG/ML Injection [Halaven]Microtubule ProcessNCIt Antineoplastic Agent TerminologyNegative Regulation of Cell Cycle

Narrower (4)

E7389ER-086526HalavenNSC 707389

Broader (2)

FuransKetones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Selectively high efficacy of eribulin against high-grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck
Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have a poor prognosis. Over… 
2018
2018
Abstract OT2-07-05: A phase III, randomized trial of sacituzumab govitecan (IMMU-132) vs treatment of physician choice (TPC) for metastatic triple-negative breast cancer (mTNBC)
Background: Metastatic TNBC has an aggressive course with limited therapy options and poor survival. Sacituzumab govitecan (IMMU… 
2017
2017
The Selective Tie 2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie 2 Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors
Tumor-infiltrating myeloid cells promote tumor progression by mediating angiogenesis, tumor cell intravasation, and metastasis… 
2017
2017
Abstract P5-15-16: Utilization and outcomes of eribulin in triple negative metastatic breast cancer: Real-world findings
Background Triple-negative breast cancer (TNBC) accounts for 10-20% of all breast cancers (BCs) and a significant proportion of… 
2016
2016
Impact of Eribulin Monotherapy on Post-Progression Survival in Patients with HER2-Negative Advanced or Metastatic Breast Cancer
C l i n M e d International Library Citation: Kotake T, Kikawa Y, Takahara S, Tsuyuki S, Yoshibayashi H, et al. (2016) Impact of… 
2013
2013
Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301
Background: The Phase III trial (NCT00337103) compared eribulin (E) with capecitabine (C) in patients (pts) with metastatic… 
2013
2013
Abstract P3-13-03: A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): Effect of post-progression anti-cancer treatments…
Background A Phase III trial (Study 301; [NCT00337103][1]) in MBC comparing eribulin (E) with capecitabine (C) showed a trend… 
2013
2013
Abstract P5-08-06: PI3K blockade enhances the antitumor activity of eribulin in PIK3CA-mutant eribulin-resistant tumor xenografts
Eribulin is a recently approved microtubule-targeting agent (MTA) for the management of heavily pretreated metastatic breast… 
2007
2007
Rapid Communication SOLICITATION FOR LETTERS OF INTENT Clinical trials Preclinical experiments E7389, Halichondrin B analog (NSC 707389)
  • 2007
  • Corpus ID: 46410751
CTEP is soliciting for phase 1 combination and phase 2 single-agent clinical trials of E7389, a halichondrin B analogue tubulin… 
2005
2005
Tubulin isotype screening in cancer therapy using the halichondrin b Analog
Chemotherapeutic agents for inhibiting the association or dissociation of microtubules in cells, is a potent inhibitor of cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)